Table 5.
Characteristics of yStage I or II patients with and without adjuvant chemotherapy.
| AT | non-AT | P-value | |
|---|---|---|---|
| (n = 23) | (n = 57) | ||
| Age (years), mean (SD) | 59.0 (10.3) | 63.7 (10.3) | 0.066 |
| Sex ratio (M:F) | 15:08 | 42:15:00 | 0.454 |
| APR, TP (Operation) | |||
| Yes | 8 (34.8) | 15 (26.3) | 0.454 |
| No | 15 (65.2) | 42 (73.7) | |
| Obstruction | |||
| Yes | 3 (13.6) | 5 (8.8) | 0.532 |
| No | 19 (86.4) | 52 (91.2) | |
| Pathological T classification | |||
| T4 | 0 (0.0) | 1 (1.8) | 0.409 |
| ≤3 | 23 (100.0) | 56 (98.3) | |
| Lymphatic invasion | |||
| Yes | 1 (4.4) | 7 (12.3) | 0.25 |
| No | 22 (95.7) | 50 (87.7) | |
| Vascular invasion | |||
| Yes | 8 (34.8) | 27 (47.4) | 0.301 |
| No | 15 (65.2) | 30 (52.6) | |
| Tumor differentiation | |||
| Poor | 6 (26.1) | 7 (12.3) | 0.143 |
| Well to moderate | 17 (73.9) | 50 (87.7) | |
| Number of lymph node resection | |||
| <12 | 7 (30.4) | 20 (35.1) | 0.689 |
| ≥12 | 16 (69.6) | 37 (64.9) | |
| CEA (ng/mL) | |||
| >5 ng/mL | 4 (17.4) | 13 (22.8) | 0.587 |
| ≤5 ng/mL | 19 (82.6) | 44 (77.2) | |
| Values are n (%) unless otherwise indicated. AT, yStage I or II patients with adjuvant therapy; non-AT, yStage I or II patients without adjuvant therapy; APR, abdominoperineal resection; TP, total pelvic exenteration; CEA, carcinoembryonic antigen. | |||